Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03347292 |
| Title | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Bayer |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | DEU |